A170900 Stock Overview
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Dong-A ST Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩75,300.00 |
52 Week High | ₩88,000.00 |
52 Week Low | ₩47,745.10 |
Beta | 0.72 |
1 Month Change | 7.27% |
3 Month Change | 8.97% |
1 Year Change | 42.23% |
3 Year Change | -6.18% |
5 Year Change | -18.39% |
Change since IPO | -47.24% |
Recent News & Updates
Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 25Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 07Recent updates
Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 25Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 07Does Dong-A ST (KRX:170900) Have A Healthy Balance Sheet?
Apr 09Dong-A ST's (KRX:170900) Problems Go Beyond Weak Profit
Mar 23A Look At The Fair Value Of Dong-A ST Co., Ltd. (KRX:170900)
Mar 12A Look At Dong-A ST's (KRX:170900) Share Price Returns
Feb 24Is Dong-A ST Co., Ltd.'s (KRX:170900) Stock's Recent Performance A Reflection Of Its Financial Health?
Feb 09Is Dong-A ST Co., Ltd. (KRX:170900) Popular Amongst Institutions?
Jan 25Is Dong-A ST Co., Ltd. (KRX:170900) A Good Fit For Your Dividend Portfolio?
Jan 11Be Sure To Check Out Dong-A ST Co., Ltd. (KRX:170900) Before It Goes Ex-Dividend
Dec 25Dong-A ST (KRX:170900) Has A Rock Solid Balance Sheet
Dec 22Calculating The Intrinsic Value Of Dong-A ST Co., Ltd. (KRX:170900)
Dec 07A Look At Dong-A ST's (KRX:170900) Share Price Returns
Nov 19Shareholder Returns
A170900 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 2.6% | 4.3% | 2.4% |
1Y | 42.2% | 28.2% | 12.2% |
Return vs Industry: A170900 exceeded the KR Pharmaceuticals industry which returned 28.2% over the past year.
Return vs Market: A170900 exceeded the KR Market which returned 12.2% over the past year.
Price Volatility
A170900 volatility | |
---|---|
A170900 Average Weekly Movement | 5.6% |
Pharmaceuticals Industry Average Movement | 4.9% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 11.9% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A170900 has not had significant price volatility in the past 3 months.
Volatility Over Time: A170900's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1932 | 1,663 | Min-Young Kim | https://www.donga-st.com |
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin for active pulmonary and extra-pulmonary tuberculosis; Dulastin and Leucostim injection for neutropenia in patients receiving myelosuppressive chemotherapy; Eporon for anemia associated with chronic renal failure; Gemcit for non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin for infertility and anovulation; Growtropin II for growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Leucostim for the treatment of neutropenia in patients receiving myelosuppressive chemotherapy; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel for breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone for use in functional dyspepsia treatment; Stillen tab for the treatment of gastritis; Suganon tab for diabetes treatment; Terizidone tab for active pulmonary and extra-pulmonary tuberculosis; and Zydena tab for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery.
Dong-A ST Co., Ltd. Fundamentals Summary
A170900 fundamental statistics | |
---|---|
Market cap | ₩649.65b |
Earnings (TTM) | ₩11.12b |
Revenue (TTM) | ₩663.98b |
57.4x
P/E Ratio1.0x
P/S RatioIs A170900 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A170900 income statement (TTM) | |
---|---|
Revenue | ₩663.98b |
Cost of Revenue | ₩339.31b |
Gross Profit | ₩324.67b |
Other Expenses | ₩313.55b |
Earnings | ₩11.12b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.31k |
Gross Margin | 48.90% |
Net Profit Margin | 1.68% |
Debt/Equity Ratio | 58.5% |
How did A170900 perform over the long term?
See historical performance and comparison